Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
BörsenkürzelPEN
Name des UnternehmensPenumbra Inc
IPO-datumSep 18, 2015
Gegründet am2004
CEOMr. Adam Elsesser, J.D.
Anzahl der mitarbeiter4500
WertpapierartOrdinary Share
GeschäftsjahresendeSep 18
AddresseOne Penumbra Place
StadtALAMEDA
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl94502
Telefon15109952486
Websitehttps://www.penumbrainc.com/
BörsenkürzelPEN
IPO-datumSep 18, 2015
Gegründet am2004
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten